Eyepoint Begins Pivotal Phase 3 Trial for Duravyu™ in DME
Phase 2 signals for EyePoint’s vorolanib intravitreal insert include an approximately 88% reduction in treatment burden at six months...
Jon Napitupulu
Surging Lung Cancer ADC Market: FDA Trials & Opportunity
Global lung cancer ADCs have moved from niche to scale: the new Kuick Research analysis pegs 2024 revenue at...
OX40 Targeted Therapy Trials & Market Opportunity Insight 2026
Across OX40/OX40L programs, concrete signals are emerging: in asthma, an amlitelimab-responsive subgroup reported more than a 70% reduction in...
Promising Pancreatic Cancer Data from Cellectar Biosciences
In three pancreatic ductal adenocarcinoma xenograft models (PANC-1, MIA PaCa-2, and BxPC-3), Cellectar’s actinium-225 phospholipid ether conjugate CLR 225...
New Analysis Supports Genetic Tool for Depression Treatment
In a retrospective re-analysis of Sanofi’s prior Phase 2 Major Depressive Disorder study (NCT00358631), patients receiving the vasopressin V1b...
Cidara Presents Late-Breaking Phase 2 CD388 Clinical Data
Cidara will deliver late-breaking Phase 2 data for its long-acting influenza prophylactic CD388 at ID Week on October 20,...
4DMT’s CF Drug Advances to Phase 2 with Foundation Support
Enrollment is underway in the Phase 2 stage of 4D Molecular Therapeutics’ AEROW trial with 2.5E14 vg set as...
Hutchmed to Present FRUSICA-2 Trial Data at ESMO Congress
Topline: In the Phase III FRUSICA-2 study (n=234) in second-line advanced renal cell carcinoma, fruquintinib plus sintilimab achieved a...
AdvanCell’s New Alpha Therapy Shows Promise for Prostate Cancer
AdvanCell’s ESMO abstract reports favorable safety and early anti-tumor activity for ADVC001, a Lead-212 (212Pb)-labeled PSMA radioligand, across seven...
Brepocitinib Poised to Fill Dermatomyositis Treatment Gap
The Phase 3 VALOR trial of brepocitinib in dermatomyositis has completed enrollment and is powered on the Total Improvement...